Investigation Report on China Nifedipine Market, 2010-2019
The incidence of cardiovascular disease has kept going up in China. Currently, 290 million Chinese are suffering from cardiovascular diseases, among which 270 million are suffering from hyper tension, 2.50 million myocardial infarction, 4.5 million heart failure, 5 million pulmonary heart disease, 2.5 million rheumatic heart disease and 5 million congenital heart disease. And one out of five adults suffers from cardiovascular disease which is the leading killer of human health. During the period of 2002-2013, coronary heart disease reported an increase in its incidence. According to the statistics of National Health and Family Planning Commission of the People’s Republic of China, the mortality of coronary heart disease in 2013 was 1008.6/1 million in city and 986.8/1 million in rural areas, both increasing slightly compared with 2012.
The synthesis of nifedipin by Bayer researchers in 1966 opened a new chapter in the treatment of cardiovascular diseases. Developed by Bayer in 1992, nifedipin controlled release tablet (Adalat) has given a new life to nifedipin and created a new dose of hypertension drug. So far, Adalat has benefited hundreds of millions of hypertension patients that include Chinese ones ever since it entered China in 1994.
Nifedipin develops fast after entering China with sales value exceeding 300 million since 2010 and 4 million in 2014. And Bayer (Germany) dominated the market with a share of over 92% in 2014 which still keeps growing. However, Bayer’s market share for sales volume was only about 60% due to its high price. Against the background that more and more people are suffering from cardiovascular diseases at a younger age, nifedipine will enjoy a vast market. And local enterprises can make use of price advantage and enhance R&D so as to take up a share in the market.
Readers can get at least the following information through this report:
market size of nifedipine in China
competitive landscape of nifedipine market in China
price of nifedipine made by different enterprises in China
market outlook of nifedipine in China
The author suggests the following groups of people purchase this report:
manufacturers of cardiovascular drugs
investors/research institutions interested in Chinese medicine market
-any interest in Chinese medicine market, please contact CRI for customized survey service
Please Note: All reports from China Research and Intelligence are written in Chinese, then translated to English. This process takes approximately 5 business days from the date the order is placed